Carterra Ships Ultra Biosensor Platform, Wraps Up 2024 With Double-Digit Growth
KUALA LUMPUR, Jan 8 (Bernama) -- Carterra Inc, the world leader in enabling high-throughput biology, announced it has delivered its first Carterra Ultra biosensor platform and closed 2024 with double-digit growth and record revenues.
Announced in September 2024, the Ultra instrument provides a full complement of small and large molecule applications while reprising gold-standard surface plasmon resonance (SPR) detection, high-throughput, and the minimal sample requirements of Carterra’s systems.
Its Chief Commercial Officer, Tim Germann acknowledged the challenges in capital equipment spending over recent years.
“Even so, drug and vaccine discovery groups are focused more than ever on going faster and spending less money to bring life-saving therapies to market, that is exactly what Carterra platforms enable,” he said in a statement.
The Ultra is capable of characterising molecules as small as 100 Daltons, with early customers utilising it to study molecular glues, PROTACS, DNA-encoded libraries (DELs), kinases, membrane proteins, and ligandability.
The platform also boasts faster analysis speeds, flexible referencing, and new screening software for fragment and small molecule applications.
For the first time, investigators can conduct fragment-based lead discovery, small-molecule analysis, and large molecule protein-protein interactions, including on- and off-target measurements at industrial scale.
Leading biopharma scientists will be showcasing groundbreaking new data generated with the Carterra Ultra platform this month with presentations at SLAS2025 International Conference & Exhibition, and Drug Discovery Chemistry 2025, both to be held in San Diego, California.
These presentations will highlight the platform's impact on advancing fragment and small molecule drug discovery while also demonstrating how Ultra enables innovative workflows and accelerates discovery timelines.
-- BERNAMA